Free Trial
NASDAQ:ADXN

Addex Therapeutics (ADXN) Stock Price, News & Analysis

Addex Therapeutics logo
$7.92 -0.21 (-2.53%)
Closing price 08/7/2025 03:58 PM Eastern
Extended Trading
$7.83 -0.10 (-1.24%)
As of 08/7/2025 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Addex Therapeutics Stock (NASDAQ:ADXN)

Key Stats

Today's Range
$8.15
$8.15
50-Day Range
$7.54
$10.23
52-Week Range
$6.51
$13.27
Volume
2,230 shs
Average Volume
1,934 shs
Market Capitalization
$8.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00
Consensus Rating
Buy

Company Overview

Addex Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

ADXN MarketRank™: 

Addex Therapeutics scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Addex Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Addex Therapeutics has received no research coverage in the past 90 days.

  • Read more about Addex Therapeutics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Addex Therapeutics is -23.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Addex Therapeutics is -23.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Addex Therapeutics has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Addex Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.15% of the float of Addex Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Addex Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Addex Therapeutics has recently decreased by 45.45%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Addex Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Addex Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.15% of the float of Addex Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Addex Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Addex Therapeutics has recently decreased by 45.45%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Addex Therapeutics insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      15.00% of the stock of Addex Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      Only 16.14% of the stock of Addex Therapeutics is held by institutions.

    • Read more about Addex Therapeutics' insider trading history.
    Receive ADXN Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Addex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    ADXN Stock News Headlines

    Addex Therapeutics Ltd (ADXN) - Yahoo Finance
    Trump’s national nightmare is here
    Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
    See More Headlines

    ADXN Stock Analysis - Frequently Asked Questions

    Addex Therapeutics' stock was trading at $7.00 at the start of the year. Since then, ADXN stock has increased by 13.2% and is now trading at $7.9240.

    Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) released its quarterly earnings results on Friday, November, 22nd. The company reported ($2.77) earnings per share for the quarter, missing the consensus estimate of ($1.40) by $1.37. Addex Therapeutics had a negative trailing twelve-month return on equity of 54.27% and a net margin of 3,584.49%.
    Read the conference call transcript
    .

    Shares of Addex Therapeutics reverse split on the morning of Monday, October 23rd 2023.The 1-20 reverse split was announced on Monday, October 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

    Shares of ADXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Addex Therapeutics investors own include Arista Networks (ANET), Adobe (ADBE), NVIDIA (NVDA), Broadcom (AVGO), GE Aerospace (GE), Vista Energy (VIST) and Arch Capital Group (ACGL).

    Company Calendar

    Last Earnings
    11/22/2024
    Today
    8/07/2025
    Next Earnings (Estimated)
    9/01/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - DRUGS
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:ADXN
    CIK
    1574232
    Employees
    30
    Year Founded
    N/A

    Price Target and Rating

    High Price Target
    $30.00
    Low Price Target
    $30.00
    Potential Upside/Downside
    +278.6%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    1 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    ($0.34)
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    $8.02 million
    Net Margins
    3,584.49%
    Pretax Margin
    -2,307.03%
    Return on Equity
    -54.27%
    Return on Assets
    -49.15%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    3.02
    Quick Ratio
    3.02

    Sales & Book Value

    Annual Sales
    $460 thousand
    Price / Sales
    18.26
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $10.37 per share
    Price / Book
    0.76

    Miscellaneous

    Outstanding Shares
    1,060,000
    Free Float
    901,000
    Market Cap
    $8.40 million
    Optionable
    Not Optionable
    Beta
    1.63

    Social Links

    These 7 Stocks Will Be Magnificent in 2025 Cover

    Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

    Get This Free Report

    This page (NASDAQ:ADXN) was last updated on 8/8/2025 by MarketBeat.com Staff
    From Our Partners